康纳斯托加退出Vertex

Conestoga's exit indicates belief that VRTX valuation multiple compression is imminent. Within 120 days, VRTX forward P/E ratio will contract by at least 15% while maintaining current earnings estimates, reflecting multiple de-rating.

The unfavorable risk-reward assessment by Conestoga reflects deteriorating pipeline prospects. VRTX will report lower-than-consensus revenue guidance in the next earnings call (within 60 days), resulting in a stock price decline of 8-12%.

Conestoga Capital's exit from Vertex signals institutional concern about VRTX valuation. Within 90 days, VRTX will underperform the Nasdaq Biotech Index (IBB) by at least 500 basis points, validating the exit decision.